BioArctic AB (publ) (BRCTF) Research

BioArctic AB (publ) is a Swedish biopharmaceutical company deeply committed to research, focusing on the creation of biological therapies for individuals affected by neurodegenerative conditions. A central element of their pipeline is BAN2401, an immunotherapy currently undergoing Phase III clinical trials. This treatment specifically targets toxic amyloid-beta oligomers and protofibrils, which are implicated in Alzheimer's disease. Furthermore, BAN2401 is also being explored in preclinical studies for its potential application in Down's syndrome with dementia and traumatic brain injury. Complementing this, BioArctic is developing BAN2401 Back-up, an antibody-based disease-modifying therapy in late preclinical stages, intended for patients in the early phases of Alzheimer's. Their broader Alzheimer's portfolio includes other experimental compounds such as AD1801, AD1502, AD1503, AD-BT2802, AD-BT2803, and AD2603. The company's developments also extend to Parkinson's disease, with ABBV-0805, a monoclonal antibody, alongside PD1601 and PD1602. For spinal cord injuries, they are advancing SC0806, a biodegradable device currently in Phase I/II clinical evaluation. Additionally, BioArctic is engaged in creating ND3014 antibodies for various neurodegenerative disorders. Beyond specific therapeutics, BioArctic pioneers research into imaging and biochemical biomarkers relevant to Alzheimer's and Parkinson's diseases. They are also advancing innovative blood-brain-barrier technology designed to facilitate the delivery of antibodies and other therapeutic substances across the blood-brain barrier into the brain. Strategic research partnerships have been established with Eisai and AbbVie. The company, initially known as BioArctic Neuroscience AB, rebranded as BioArctic AB (publ) in 2016. BioArctic was founded in 1992 and maintains its headquarters in Stockholm, Sweden.

Open BioArctic AB (publ) (BRCTF) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.